Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted by FDA Week in “FDA Should Define Company ‘Influence’ On Social Media Platforms.”
Following is an excerpt:
Bradley Merrill Thompson, an attorney at Epstein Becker & Green, said FDA should nail down parameters for the term to avoid Constitutional scrutiny. "I honestly wouldn't know how to navigate social media if I had to be concerned about simply influencing someone," said Thompson. "I think people would be paralyzed not knowing their limits on what they could do."